Beckman Coulter Licenses Johns Hopkins Cancer IP for Dx Development

Oct 30, 2007

NEW YORK (GenomeWeb News) — Beckman Coulter has inked two deals with Johns Hopkins University for exclusive licenses to intellectual property tied to cancer genomics research, the company said today.

Terms of the agreements give Beckman Coulter the “exclusive option to license any of the genetic mutations discovered in these studies that have diagnostic potential,” Bruce Wallace, vice president of Beckman Coulter's Molecular Diagnostics Business Center, said in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

An RNAi Approval

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Keep It Going

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

Stop It There

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

This Week in PLOS

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.

Main menu